The aim of this pilot study was to determine whether the use of induced hypertension in acute stroke is feasible and associated with neurologic improvement. Phenylephrine was used to raise the systolic blood pressure in patients with acute stroke by 20%, not to exceed 200 mmHG: Of 13 patients treated, 7 improved by 2 points on the NIH Stroke SCALE: No systemic or neurologic complications were seen. The authors conclude that induced hypertension in acute stroke is feasible and likely safe and can improve the neurologic examination in some patients.

The risks to patients with metal surgical implants who are undergoing nuclear magnetic resonance (NMR) imaging and the artifacts caused by such implants were studied. Twenty-one aneurysm and other hemostatic clips and a variety of other materials (e.g., dental amalgam, 14 karat gold) were used. Longitudinal forces and torques were found to be exerted upon 16 of the 21 clips. With five aneurysm clips, forces and torques sufficient to produce risk of hemorrhage from dislocation of the clip from the vessel or aneurysm, or cerebral injury by clip displacement without dislodgement were identified. The induced ferromagnetism was shown to be related to the composition of the alloys from which the clips were manufactured. Clips with 10-14% nickel are evidently without sufficient induced ferromagnetism to cause hazard. The extent of NMR imaging artifacts was greater for materials with measurable ferromagnetic properties, but metals without measurable ferromagnetism in our tests also resulted in significant artifacts. Dental amalgam and 14 karat gold produced no imaging artifacts, but stainless steels in dentures and orthodontic braces produced extensive artifacts in the facial region.

SUMMARY:Reperfusion remains the mainstay of acute ischemic stroke treatment. Endovascular therapy has become a promising alternative for patients who are ineligible for or have failed intravenous (IV) thrombolysis. The conviction that recanalization of properly selected patients is essential for the achievement of good clinical outcomes has led to the rapid and widespread growth in the adoption of endovascular stroke therapies. However, comparisons of the recent reperfusion studies have brought into question the strength of the association between revascularization and improved clinical outcome. Despite higher rates of recanalization, the mechanical thrombectomy studies have demonstrated substantially lower rates of good outcomes compared with IV and/or intra-arterial thrombolytic trials. However, such analyses disregard important differences in clot location and burden, baseline stroke severity, time from stroke onset to treatment, and patient selection in these studies. Many clinical trials are testing novel devices and drugs as well as the paradigm of physiology-based stroke imaging as a treatment-selection tool. The objective of this article is to provide a comprehensive review of the relevant past, current, and upcoming data on endovascular stroke therapy with a special focus on the prospective studies and randomized clinical trials. Mirroring its intravenous (IV) counterpart, much of the early work in endovascular stroke therapy has been reported in nonrandomized case series. Reports of successful intra-arterial thrombolysis (IAT) date back to the late 1950s, when Sussmann and Fitch 1 described the recanalization of an acutely occluded internal carotid artery (ICA) with intra-arterial (IA) injection of plasmin. Although pioneering work continued, it was not until the early 1990s that IAT was studied in a more systematic manner. In 2002, Lisboa et al 2 published a meta-analysis regarding the safety and efficacy of this approach. They performed a meta-analysis of 27 studies (minimum of 10 patients in each) with a total of 852 patients who had received IAT and 100 control subjects, in the era before the mechanical thrombectomy trials.3-5 There were more favorable outcomes in the IAT group than in the control group (41.5% versus 23%, P ϭ .002), with a lower mortality rate for IAT (27.2% versus 40%, P ϭ .004). The IAT group had an odds ratio (OR) of 2.4 (95% confidence interval [CI,], 1.45-3.85) for favorable outcome, despite a higher frequency of symptomatic intracranial hemorrhage (SICH; 9.5% versus 3%, P ϭ .046). In addition, they found a trend toward better outcomes with combined IV recombinant tissue plasminogen activator (rtPA) and IAT than with IAT alone. They also remarked that IAT-treated supratentorial strokes were more likely to have favorable outcomes than infratentorial ones (42.2% versus 25.6%, P ϭ .001; OR, 2.0; 95% CI, 1.33-3.0).A recent retrospective study compared 144 patients treated with IAT by using urokinase (UK) within 6 hours of symptom onset versus 147 patients treated with aspirin (250...